Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer

NCT04985266 is registered in ClinicalTrials.gov with Royal Marsden NHS Foundation Trust as lead sponsor.

NCT NCT04985266
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04985266 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
Lead sponsor
Royal Marsden NHS Foundation Trust
Phase
Phase 2
Overall status
Recruiting
Start date
March 30, 2022
Completion date
September 1, 2030
Enrollment
1,100 (estimated)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

er+ breast cancer, her2-negative breast cancer